AR054536A1 - Terapia de combinacion de anticuerpo anti- ctla -4 y oligodesoxinucleotido sintetico que contiene motivo cgp para el tratamiento del cancer - Google Patents
Terapia de combinacion de anticuerpo anti- ctla -4 y oligodesoxinucleotido sintetico que contiene motivo cgp para el tratamiento del cancerInfo
- Publication number
- AR054536A1 AR054536A1 ARP060102913A ARP060102913A AR054536A1 AR 054536 A1 AR054536 A1 AR 054536A1 AR P060102913 A ARP060102913 A AR P060102913A AR P060102913 A ARP060102913 A AR P060102913A AR 054536 A1 AR054536 A1 AR 054536A1
- Authority
- AR
- Argentina
- Prior art keywords
- ctla
- oligodesoxinucleotido
- synthetic
- reason
- combination therapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 2
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 abstract 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009093 first-line therapy Methods 0.000 abstract 1
- 102000043321 human CTLA4 Human genes 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 229960005386 ipilimumab Drugs 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 238000009099 neoadjuvant therapy Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 238000009094 second-line therapy Methods 0.000 abstract 1
- 238000009095 third-line therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Administracion de un anticuerpo anti-CTLA-4, particularmente anticuerpos humanos contra CTLA-4 humano, tales como aquellos que tienen secuencias de aminoácidos de anticuerpos 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, y MDX-010, en combinacion con un nucleotido inmunoestimulador, es decir CpG ODN PF3512676 para el tratamiento del cáncer. La administracion de una combinacion de un anticuerpo anti-CTLA-4 y CpG ODN PF3512676 como terapia neoadyuvante, adyuvante, de primera línea, segunda línea y tercera línea para el cáncer, ya sea localizado o metastásico, y en cualquier punto a lo largo de la escala continua de la enfermedad (por ej., en cualquier etapa del cáncer).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69708205P | 2005-07-07 | 2005-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054536A1 true AR054536A1 (es) | 2007-06-27 |
Family
ID=37492285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102913A AR054536A1 (es) | 2005-07-07 | 2006-07-06 | Terapia de combinacion de anticuerpo anti- ctla -4 y oligodesoxinucleotido sintetico que contiene motivo cgp para el tratamiento del cancer |
Country Status (17)
Country | Link |
---|---|
US (2) | US20090117132A1 (es) |
EP (1) | EP1904530A2 (es) |
JP (1) | JP2009500412A (es) |
KR (1) | KR20080030656A (es) |
CN (1) | CN101268101A (es) |
AR (1) | AR054536A1 (es) |
AU (1) | AU2006269555A1 (es) |
BR (1) | BRPI0612408A2 (es) |
CA (1) | CA2614320A1 (es) |
EA (1) | EA200800268A1 (es) |
IL (1) | IL188588A0 (es) |
MX (1) | MX2008000379A (es) |
NZ (1) | NZ565311A (es) |
SG (1) | SG163583A1 (es) |
TW (1) | TW200801042A (es) |
WO (1) | WO2007008463A2 (es) |
ZA (1) | ZA200801190B (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
CA2328406A1 (en) * | 1998-05-14 | 1999-11-18 | Hermann Wagner | Methods for regulating hematopoiesis using cpg-oligonucleotides |
AU2003230806B2 (en) | 2002-04-04 | 2009-05-07 | Zoetis Belgium S.A. | Immunostimulatory G,U-containing oligoribonucleotides |
AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
AU2004226605A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
KR101107818B1 (ko) * | 2003-10-30 | 2012-01-31 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 향상된 면역자극 효능을 가진 c-부류 올리고뉴클레오티드유사체 |
EP1945766A2 (en) * | 2005-09-16 | 2008-07-23 | Coley Pharmaceutical GmbH | Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone |
EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
CA3033133C (en) | 2009-03-25 | 2021-11-09 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
SI2769737T1 (sl) * | 2009-07-20 | 2017-06-30 | Bristol-Myers Squibb Company | Kombinacija anti-ctla4 protitelesa z etoposidom za sinergistično zdravljenje proliferativnih bolezni |
WO2011014438A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
EP2525780B1 (en) | 2010-01-19 | 2022-09-07 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
EP2734232B1 (en) * | 2011-07-19 | 2017-11-01 | Philogen S.p.A. | Sequential anti-ctla4 and targeted il-2 therapy |
US20130210896A1 (en) * | 2011-11-09 | 2013-08-15 | City Of Hope | Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System |
PE20142406A1 (es) | 2012-05-04 | 2015-01-23 | Pfizer | Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna |
CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
CN112107693B (zh) | 2013-12-03 | 2023-05-26 | 西北大学 | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 |
EP3508198A1 (en) | 2014-06-04 | 2019-07-10 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
WO2016057549A1 (en) | 2014-10-06 | 2016-04-14 | Aurasense Therapeutics, Llc | Anti-tnf compounds |
EP4029508A1 (en) * | 2014-10-10 | 2022-07-20 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonists and checkpoint inhibitors |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
AU2015374385B2 (en) | 2014-12-31 | 2020-08-06 | Checkmate Pharmaceuticals, Inc. | Combination tumor immunotherapy |
CA2985055C (en) * | 2015-04-03 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Combination therapy to treat cancer comprising dendritic cells engineered to overexpress p53 and an immune checkpoint inhibitor |
UA125611C2 (uk) | 2015-12-14 | 2022-05-04 | Макродженікс, Інк. | Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування |
CN106893724B (zh) * | 2015-12-17 | 2023-05-02 | 苏州派动生物技术有限公司 | 具有抗原增效作用和肿瘤治疗作用的寡核苷酸 |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP3436066A1 (en) | 2016-04-01 | 2019-02-06 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
JP7062599B2 (ja) * | 2016-05-06 | 2022-05-06 | イグジキュア オペレーティング カンパニー | 強力な抗腫瘍活性を有するtlr9を標的化する球状核酸 |
US20200255837A9 (en) * | 2016-05-06 | 2020-08-13 | Exicure, Inc. | Spherical nucleic acid tlr9 agonists |
CN107400166A (zh) | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
KR102531889B1 (ko) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | 항-pd-l1 및 il-2 사이토카인 |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US10463686B2 (en) | 2016-09-15 | 2019-11-05 | Idera Pharmaceuticals, Inc. | Immune modulation with TLR9 agonists for cancer treatment |
WO2018160536A1 (en) * | 2017-02-28 | 2018-09-07 | Bristol-Myers Squibb Company | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine |
EP3603668A4 (en) * | 2017-03-29 | 2021-01-06 | Terumo Kabushiki Kaisha | ADDITIVE COMPOSITION, VACCINE COMPOSITION AND MEDICINAL KIT WITH IT |
KR20200028997A (ko) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법 |
WO2019160866A2 (en) * | 2018-02-13 | 2019-08-22 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
AU2019251421A1 (en) | 2018-04-09 | 2020-10-29 | Checkmate Pharmaceuticals | Packaging oligonucleotides into virus-like particles |
CN108486120B (zh) * | 2018-04-28 | 2019-12-06 | 新乡医学院 | 一种新型CpG ODN序列及其在抗黑色素瘤上的应用 |
BR112021000065A2 (pt) * | 2018-07-10 | 2021-04-06 | Sanofi | Terapias de combinação contra câncer direcionando cd38 e tgf-beta |
CN111321159B (zh) * | 2018-12-14 | 2023-12-12 | 中天(上海)生物科技有限公司 | 用于免疫调节的嵌合核酸分子及其应用 |
US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
EP3983440A1 (en) * | 2019-06-13 | 2022-04-20 | CytomX Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer |
TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | 包含il-7變體之雙官能分子 |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
CA3213917A1 (en) | 2021-04-09 | 2022-10-13 | Nicolas Poirier | New scaffold for bifunctional molecules with improved properties |
EP4326321A1 (en) | 2021-04-20 | 2024-02-28 | Institut Curie | Compositions and methods for use in immunotherapy |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5308626A (en) * | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE420171T1 (de) * | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US5780448A (en) * | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
US6030955A (en) * | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
EP0930893B1 (en) * | 1996-10-11 | 2005-04-13 | The Regents of The University of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US6214806B1 (en) * | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6426334B1 (en) * | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
CA2301575C (en) * | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1009440B1 (en) * | 1997-07-03 | 2008-09-17 | MacFarlane, Donald E. | Method for inhibiting immunostimulatory dna associated responses |
US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US20050031638A1 (en) * | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
DE69935507T2 (de) * | 1998-04-03 | 2007-12-06 | University Of Iowa Research Foundation | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
CA2328406A1 (en) * | 1998-05-14 | 1999-11-18 | Hermann Wagner | Methods for regulating hematopoiesis using cpg-oligonucleotides |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US20020065236A1 (en) * | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
PT2112166T (pt) * | 1998-12-23 | 2019-01-30 | Pfizer | Anticorpos monoclonais humanos contra ctla-4 |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
DE19935756A1 (de) * | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
KR100942863B1 (ko) * | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
DK1221955T3 (da) * | 1999-09-25 | 2006-01-30 | Univ Iowa Res Found | Immunstimulerende nukleinsyre |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
AU2001249609A1 (en) * | 2000-03-28 | 2001-10-08 | Department Of Veterans Affairs | Methods for increasing a cytotoxic T lymphocyte response in vivo |
AU2001274817A1 (en) * | 2000-05-05 | 2001-11-20 | The Regents Of The University Of California | Agents that modulate dna-pk activity and methods of use thereof |
PT1296714E (pt) * | 2000-06-22 | 2009-10-15 | Coley Pharm Gmbh | Combinação de cpg e anticorpos dirigidos contra cd19, cd20, cd22 ou cd40 para o tratamento ou prevenção do cancro |
US20020091097A1 (en) * | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
FR2814958B1 (fr) * | 2000-10-06 | 2003-03-07 | Aventis Pasteur | Composition vaccinale |
GB0025577D0 (en) * | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
WO2002053141A2 (en) * | 2000-12-14 | 2002-07-11 | Coley Pharmaceutical Group, Inc. | Inhibition of angiogenesis by nucleic acids |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
WO2003103586A2 (en) * | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
ATE536188T1 (de) * | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
CA2511625A1 (en) * | 2002-12-23 | 2004-07-15 | City Of Hope | Modified vaccinia ankara expressing p53 in cancer immunotherapy |
WO2005016235A2 (en) * | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
ATE476196T1 (de) * | 2003-06-17 | 2010-08-15 | Mannkind Corp | Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke |
MXPA05013922A (es) * | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
EP1730281A2 (en) * | 2004-04-02 | 2006-12-13 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing il-10 responses |
AU2005326144A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
WO2006134423A2 (en) * | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
JP2008518902A (ja) * | 2004-11-04 | 2008-06-05 | ファイザー・プロダクツ・インク | 乳癌のためのctla4抗体とアロマターゼ阻害剤の併用治療 |
US20080009455A9 (en) * | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
KR20080072934A (ko) * | 2005-11-25 | 2008-08-07 | 콜리 파마슈티칼 게엠베하 | 면역자극성 올리고리보뉴클레오티드 |
JP5473336B2 (ja) * | 2006-02-15 | 2014-04-16 | アディウタイド・ファーマスーティカルズ・ゲーエムベーハー | オリゴヌクレオチドの処方に関する組成物および方法 |
-
2006
- 2006-06-30 NZ NZ565311A patent/NZ565311A/en not_active IP Right Cessation
- 2006-06-30 EP EP06786046A patent/EP1904530A2/en not_active Withdrawn
- 2006-06-30 WO PCT/US2006/025711 patent/WO2007008463A2/en active Application Filing
- 2006-06-30 BR BRPI0612408-9A patent/BRPI0612408A2/pt not_active Application Discontinuation
- 2006-06-30 AU AU2006269555A patent/AU2006269555A1/en not_active Abandoned
- 2006-06-30 US US11/988,396 patent/US20090117132A1/en not_active Abandoned
- 2006-06-30 KR KR1020087003206A patent/KR20080030656A/ko not_active Application Discontinuation
- 2006-06-30 CN CNA2006800325204A patent/CN101268101A/zh active Pending
- 2006-06-30 SG SG201004913-8A patent/SG163583A1/en unknown
- 2006-06-30 EA EA200800268A patent/EA200800268A1/ru unknown
- 2006-06-30 JP JP2008520309A patent/JP2009500412A/ja active Pending
- 2006-06-30 CA CA002614320A patent/CA2614320A1/en not_active Abandoned
- 2006-06-30 MX MX2008000379A patent/MX2008000379A/es unknown
- 2006-07-03 TW TW095124152A patent/TW200801042A/zh unknown
- 2006-07-06 AR ARP060102913A patent/AR054536A1/es unknown
-
2008
- 2008-01-03 IL IL188588A patent/IL188588A0/en unknown
- 2008-02-04 ZA ZA200801190A patent/ZA200801190B/xx unknown
-
2011
- 2011-06-24 US US13/168,206 patent/US20120003179A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2614320A1 (en) | 2007-01-18 |
US20090117132A1 (en) | 2009-05-07 |
AU2006269555A1 (en) | 2007-01-18 |
NZ565311A (en) | 2009-10-30 |
ZA200801190B (en) | 2008-12-31 |
WO2007008463A3 (en) | 2007-05-24 |
WO2007008463A2 (en) | 2007-01-18 |
IL188588A0 (en) | 2008-04-13 |
US20120003179A1 (en) | 2012-01-05 |
KR20080030656A (ko) | 2008-04-04 |
JP2009500412A (ja) | 2009-01-08 |
BRPI0612408A2 (pt) | 2010-11-03 |
EP1904530A2 (en) | 2008-04-02 |
MX2008000379A (es) | 2008-03-18 |
TW200801042A (en) | 2008-01-01 |
CN101268101A (zh) | 2008-09-17 |
SG163583A1 (en) | 2010-08-30 |
EA200800268A1 (ru) | 2008-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054536A1 (es) | Terapia de combinacion de anticuerpo anti- ctla -4 y oligodesoxinucleotido sintetico que contiene motivo cgp para el tratamiento del cancer | |
AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
BRPI0514721A (pt) | uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo | |
CY1120879T1 (el) | Πολλαπλου συστατικου βιοδραστικος ενδοκολπικος δακτυλιος | |
ATE466084T1 (de) | Hla-a24-restringiertes krebsantigenpeptid | |
GT200600092A (es) | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer | |
BR112019021822A2 (pt) | Terapia de combinação | |
AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
CR20170130A (es) | Formulaciones de pepticuerpos terapéuticos liofilizados | |
AR063760A1 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
UA105210C2 (ru) | Противораковая вакцина и ее применение | |
BRPI0418463A (pt) | métodos de inibir expressão de stat3 humano, de induzir apoptose em células de carcinoma do pulmão, e de inibir crescimento de tumor de linfoma de células t, tumor alcl, e tumor mieloma múltiplo em um animal | |
TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
HK1091127A1 (en) | Compounds and methods for downregulating the effects of tgf-beta | |
WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
BRPI0417823A (pt) | métodos para uso de bifidobactérias probióticas para animais de estimação | |
TW200612918A (en) | Lonidamine analogs | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
MXPA05012421A (es) | Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. | |
BRPI0511420A (pt) | fosforodiamidatos de sulfoniletila | |
AR056801A1 (es) | Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina | |
AR080891A1 (es) | Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores | |
UA99601C2 (ru) | Применение антитела к cd151 для лечения первичных опухолей | |
WO2002096348A3 (fr) | Produit comprenant du mikanolide ou du dihydromikanolide en association avec un autre agent anti-cancereux |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |